Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Genes, Chromosomes & Cancer|April 15, 2014
14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphomaAdrien Cosson, Elise Chapiro, Nabila Belhouachi, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Pageof 7